ATW SPAC Management’s AEON Biopharma AEON Stock Holding History

ATW SPAC Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-875	Closed	-$633K	–	184
2022 Q4	$633K	Hold	875	–	–	0.15%	97
2022 Q3	$621K	Buy	+875	New	+$620K	0.1%	141

Other funds holding AEON

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

ATW SPAC Management's AEON Position: Q1 2023 in Review

ATW SPAC Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 875 shares — an estimated $633K sold.

ATW SPAC Management first reported a position in AEON in Q3 2022 and held it in 2 quarters. The position peaked at $633K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

ATW SPAC Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
ATW SPAC Management sold 875 AEON Biopharma shares in Q1 2023, an estimated $633K.
ATW SPAC Management first reported a position in AEON Biopharma in Q3 2022 and held it in 2 quarters.
ATW SPAC Management's AEON Biopharma position peaked at $633K in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on ATW SPAC Management's 13F filing for Q1 2023, filed 15 May 2023.